See more : Caro Holdings Inc. (CAHO) Income Statement Analysis – Financial Results
Complete financial analysis of ImmunoGen, Inc. (IMGN) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of ImmunoGen, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Western Pacific Minerals Ltd. (WPMLF) Income Statement Analysis – Financial Results
- Marchex, Inc. (MCHX) Income Statement Analysis – Financial Results
- CTEEP – Companhia de Transmissão de Energia Elétrica Paulista S.A. (TRPL3.SA) Income Statement Analysis – Financial Results
- Oisix ra daichi Inc. (OISXF) Income Statement Analysis – Financial Results
- Taiwan Advance Bio-Pharmaceutical Inc. (4186.TWO) Income Statement Analysis – Financial Results
ImmunoGen, Inc. (IMGN)
About ImmunoGen, Inc.
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sunirine, a CD123-targeting ADC that is in Phase II clinical trial for treating acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm. Its preclinical programs include IMGC936, an ADC in co-development with MacroGenics, Inc.; and IMGN151, an anti FRa product candidate. The company has collaborations with Roche; Amgen/Oxford BioTherapeutics; Bayer HealthCare AG; Eli Lilly and Company; Novartis Institutes for BioMedical Research, Inc.; CytomX Therapeutics, Inc.; Fusion Pharmaceuticals Inc.; Debiopharm International SA; and MacroGenics, Inc. ImmunoGen, Inc. was founded in 1980 and is headquartered in Waltham, Massachusetts.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 | 1992 | 1991 | 1990 | 1989 | 1988 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 108.78M | 108.78M | 132.30M | 82.27M | 53.82M | 115.45M | 48.63M | 60.00M | 85.54M | 59.90M | 35.54M | 16.36M | 19.31M | 13.94M | 27.99M | 40.25M | 38.21M | 32.09M | 35.72M | 25.96M | 7.63M | 5.88M | 4.48M | 11.18M | 3.70M | 600.00K | 400.00K | 500.00K | 500.00K | 900.00K | 1.70M | 2.70M | 3.40M | 1.00M | 800.00K |
| Cost of Revenue | 176.00K | 176.00K | 114.59M | 114.52M | 173.89M | 139.74M | 141.31M | 146.92M | 111.77M | 106.96M | 87.07M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 3.57M | 2.67M | 9.24M | 5.66M | 2.83M | 3.34M | 597.05K | -463.45K | -500.00K | -1.10M | -1.50M | -6.00M | 13.40M | 17.90M | -1.70M | -1.30M | 9.50M | 7.10M | 4.70M |
| Gross Profit | 108.61M | 108.61M | 17.71M | -32.25M | -120.07M | -24.29M | -92.68M | -86.91M | -26.23M | -47.06M | -51.54M | 16.36M | 19.31M | 13.94M | 27.99M | 40.25M | 34.64M | 29.42M | 26.48M | 20.30M | 4.79M | 2.54M | 3.88M | 11.64M | 4.20M | 1.70M | 1.90M | 6.50M | -12.90M | -17.00M | 3.40M | 4.00M | -6.10M | -6.10M | -3.90M |
| Gross Profit Ratio | 99.84% | 99.84% | 13.38% | -39.20% | -223.11% | -21.04% | -190.60% | -144.85% | -30.66% | -78.57% | -145.03% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 90.65% | 91.69% | 74.14% | 78.20% | 62.84% | 43.21% | 86.67% | 104.15% | 113.51% | 283.33% | 475.00% | 1,300.00% | -2,580.00% | -1,888.89% | 200.00% | 148.15% | -179.41% | -610.00% | -487.50% |
| Research & Development | 213.37M | 213.37M | 114.59M | 114.52M | 173.89M | 139.74M | 141.31M | 146.92M | 111.77M | 106.96M | 87.07M | 69.19M | 63.45M | 50.28M | 45.90M | 60.01M | 45.84M | 40.91M | 30.54M | 22.22M | 23.43M | 17.69M | 15.21M | 8.88M | 6.10M | 6.60M | 7.40M | 9.60M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 0.00 | 43.81M | 38.60M | 38.49M | 36.72M | 33.91M | 38.53M | 36.92M | 28.23M | 24.47M | 21.47M | 20.42M | 16.04M | 14.90M | 13.90M | 14.35M | 11.03M | 9.90M | 8.77M | 6.63M | 5.96M | 5.40M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 72.32M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 116.13M | 116.13M | 38.60M | 38.49M | 36.72M | 33.91M | 38.53M | 36.92M | 28.23M | 24.47M | 21.47M | 20.42M | 16.04M | 14.90M | 13.90M | 14.35M | 11.03M | 9.90M | 8.77M | 6.63M | 5.96M | 5.40M | 4.48M | 3.06M | 1.80M | 1.70M | 2.20M | 1.80M | 3.00M | 4.50M | 20.20M | 18.00M | 1.40M | 1.40M | 1.00M |
| Other Expenses | 3.35M | 3.35M | 1.21M | 5.01M | 3.33M | 2.61M | 0.00 | 304.00K | -848.00K | 167.00K | 198.00K | 64.68M | 56.20M | 44.92M | 38.34M | 44.98M | 23.92M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 463.45K | 500.00K | 1.10M | 1.50M | 6.00M | 3.40M | 2.00M | 1.70M | 1.30M | 1.10M | 700.00K | 300.00K |
| Operating Expenses | 329.50M | 329.50M | 153.19M | 153.01M | 210.60M | 173.65M | 43.54M | 183.83M | 140.00M | 131.43M | 108.54M | 89.61M | 79.49M | 65.18M | 59.80M | 74.36M | 56.87M | 50.81M | 39.30M | 28.86M | 29.39M | 23.10M | 19.69M | 12.40M | 8.40M | 9.40M | 11.10M | 17.40M | 6.40M | 6.50M | 21.90M | 19.30M | 2.50M | 2.10M | 1.30M |
| Cost & Expenses | 329.68M | 329.68M | 153.19M | 153.01M | 210.60M | 173.65M | 184.85M | 183.83M | 140.00M | 131.43M | 108.54M | 89.61M | 79.49M | 65.18M | 59.80M | 74.36M | 60.44M | 53.47M | 48.54M | 34.51M | 32.22M | 26.44M | 20.29M | 11.94M | 7.90M | 8.30M | 9.60M | 11.40M | 19.80M | 24.40M | 20.20M | 18.00M | 12.00M | 9.20M | 6.00M |
| Interest Income | 4.34M | 51.00K | 729.00K | 4.42M | 0.00 | 0.00 | 20.51M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 4.17M | 4.17M | 23.20M | 16.97M | 10.73M | 16.72M | 0.00 | 20.13M | 5.44M | 0.00 | 0.00 | 62.00K | 0.00 | 0.00 | 221.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 100.00K | 0.00 | 0.00 |
| Depreciation & Amortization | 3.35M | -1.08M | 115.80M | 26.45M | 7.41M | 5.96M | 6.01M | 5.33M | 5.51M | 4.60M | 4.64M | 4.63M | 4.94M | 4.84M | 5.00M | 3.93M | 3.15M | 2.69M | 2.22M | 1.29M | 1.13M | 984.76K | 612.82K | 463.45K | 500.00K | 1.10M | 1.50M | 6.00M | 3.40M | 2.00M | 1.70M | 1.30M | 1.10M | 700.00K | 300.00K |
| EBITDA | -217.55M | -217.55M | -19.68M | -65.73M | -153.45M | -55.60M | -125.20M | -123.53M | -55.30M | -71.53M | -73.01M | -73.20M | -62.10M | -51.29M | -31.60M | -32.30M | -22.35M | -18.99M | -10.53M | -8.59M | -25.42M | -20.57M | -15.66M | -366.61K | -3.80M | -6.60M | -7.90M | -3.00M | -15.90M | -21.50M | -16.80M | -14.00M | -7.50M | -7.50M | -4.90M |
| EBITDA Ratio | -199.98% | -199.98% | -14.88% | -79.89% | -285.15% | -48.16% | -257.46% | -205.87% | -64.65% | -119.43% | -205.46% | -447.48% | -321.69% | -367.88% | -112.89% | -80.25% | -58.48% | -59.19% | -29.47% | -33.09% | -333.30% | -349.63% | -349.69% | -3.28% | -102.70% | -1,100.00% | -1,975.00% | -600.00% | -3,180.00% | -2,388.89% | -988.24% | -518.52% | -220.59% | -750.00% | -612.50% |
| Operating Income | -220.89M | -220.89M | -135.49M | -92.17M | -160.48M | -58.98M | -131.21M | -123.83M | -54.46M | -71.53M | -73.01M | -73.26M | -60.19M | -51.24M | -31.82M | -34.11M | -22.23M | -21.39M | -12.82M | -8.56M | -24.59M | -20.56M | -15.81M | -761.00K | -4.20M | -7.70M | -9.20M | -10.90M | -19.30M | -23.50M | -18.50M | -15.30M | -8.60M | -8.20M | -5.20M |
| Operating Income Ratio | -203.06% | -203.06% | -102.41% | -112.04% | -298.20% | -51.09% | -269.83% | -206.37% | -63.66% | -119.43% | -205.46% | -447.86% | -311.77% | -367.46% | -113.68% | -84.75% | -58.16% | -66.65% | -35.90% | -32.97% | -322.39% | -349.41% | -353.01% | -6.81% | -113.51% | -1,283.33% | -2,300.00% | -2,180.00% | -3,860.00% | -2,611.11% | -1,088.24% | -566.67% | -252.94% | -820.00% | -650.00% |
| Total Other Income/Expenses | -818.00K | -14.23M | -21.99M | -11.96M | -8.36M | -37.03M | -25.52M | -19.83M | -6.28M | 167.00K | 198.00K | -62.00K | 1.91M | 58.00K | -221.00K | 2.12M | 3.27M | 3.57M | 1.90M | 2.69M | 4.65M | 6.05M | 6.34M | 523.44K | 100.00K | 100.00K | 200.00K | -5.60M | -600.00K | -200.00K | -100.00K | 0.00 | -100.00K | -100.00K | -100.00K |
| Income Before Tax | -221.71M | -221.71M | -44.37M | -104.13M | -167.87M | -96.01M | -156.73M | -143.66M | -60.74M | -71.36M | -72.81M | -73.32M | -58.27M | -51.18M | -32.04M | -31.99M | -18.95M | -17.82M | -10.92M | -5.87M | -19.95M | -14.50M | -9.47M | -237.56K | -4.10M | -7.60M | -9.00M | -16.50M | -19.90M | -23.70M | -18.60M | -15.30M | -8.70M | -8.30M | -5.30M |
| Income Before Tax Ratio | -203.81% | -203.81% | -33.54% | -126.57% | -311.94% | -83.17% | -322.31% | -239.42% | -71.01% | -119.15% | -204.90% | -448.24% | -301.86% | -367.04% | -114.47% | -79.49% | -49.60% | -55.53% | -30.58% | -22.62% | -261.49% | -246.51% | -211.49% | -2.12% | -110.81% | -1,266.67% | -2,250.00% | -3,300.00% | -3,980.00% | -2,633.33% | -1,094.12% | -566.67% | -255.88% | -830.00% | -662.50% |
| Income Tax Expense | 1.22M | 1.22M | 22.31M | 17.96M | 7.39M | 37.03M | 0.00 | 19.83M | 6.28M | -167.00K | -198.00K | 62.00K | -1.91M | -265.00K | -100.00K | 27.00K | 35.00K | 17.00K | 29.00K | 45.49K | 35.13K | 127.81K | 82.60K | 237.56K | 4.10M | 7.60M | 9.00M | 16.50M | 19.90M | 23.70M | 18.60M | 15.30M | 100.00K | 8.30M | 5.30M |
| Net Income | -222.93M | -222.93M | -66.68M | -122.09M | -167.87M | -96.01M | -156.73M | -143.66M | -60.74M | -71.36M | -72.81M | -73.32M | -58.27M | -50.91M | -31.94M | -32.02M | -18.99M | -17.83M | -10.95M | -5.92M | -19.98M | -14.63M | -15.29M | -237.56K | -4.10M | -7.60M | -9.00M | -16.50M | -19.90M | -23.70M | -18.60M | -15.30M | -8.80M | -8.30M | -5.30M |
| Net Income Ratio | -204.93% | -204.93% | -50.40% | -148.40% | -311.94% | -83.17% | -322.31% | -239.42% | -71.01% | -119.15% | -204.90% | -448.24% | -301.86% | -365.14% | -114.11% | -79.55% | -49.69% | -55.58% | -30.66% | -22.80% | -261.95% | -248.68% | -341.36% | -2.12% | -110.81% | -1,266.67% | -2,250.00% | -3,300.00% | -3,980.00% | -2,633.33% | -1,094.12% | -566.67% | -258.82% | -830.00% | -662.50% |
| EPS | -0.88 | -0.88 | -0.38 | -0.82 | -1.20 | -0.98 | -1.80 | -1.65 | -0.71 | -0.83 | -0.87 | -0.95 | -0.85 | -0.87 | -0.63 | -0.75 | -0.45 | -0.43 | -0.27 | -0.15 | -0.48 | -0.37 | -0.42 | -0.01 | -0.16 | -0.31 | -0.50 | -1.32 | -1.58 | -2.09 | -1.76 | -1.58 | -1.28 | -1.46 | -3.36 |
| EPS Diluted | -0.88 | -0.88 | -0.38 | -0.82 | -1.20 | -0.98 | -1.80 | -1.65 | -0.71 | -0.83 | -0.87 | -0.95 | -0.85 | -0.87 | -0.63 | -0.75 | -0.45 | -0.43 | -0.27 | -0.15 | -0.48 | -0.37 | -0.42 | -0.01 | -0.16 | -0.31 | -0.50 | -1.32 | -1.58 | -2.09 | -1.76 | -1.58 | -1.28 | -1.46 | -3.36 |
| Weighted Avg Shares Out | 253.33M | 253.63M | 176.15M | 148.31M | 139.95M | 98.07M | 87.08M | 86.98M | 86.04M | 85.48M | 84.06M | 76.81M | 68.92M | 58.85M | 51.07M | 42.97M | 41.76M | 41.18M | 40.87M | 40.65M | 41.91M | 39.62M | 36.68M | 29.52M | 25.53M | 24.21M | 17.86M | 12.50M | 12.57M | 11.34M | 10.57M | 9.68M | 6.88M | 5.68M | 1.58M |
| Weighted Avg Shares Out (Dil) | 253.63M | 253.63M | 176.15M | 148.31M | 139.95M | 98.07M | 87.08M | 86.98M | 86.04M | 85.48M | 84.06M | 76.81M | 68.92M | 58.85M | 51.07M | 42.97M | 41.76M | 41.18M | 40.87M | 40.65M | 41.91M | 39.62M | 36.68M | 32.85M | 25.53M | 24.21M | 17.86M | 12.50M | 12.62M | 11.34M | 10.57M | 9.68M | 6.88M | 5.68M | 1.58M |
ImmunoGen (IMGN) Gets FDA Priority Review for Elahere sBLA
The FDA grants priority review to ImmunoGen's (IMGN) sBLA to convert the accelerated approval for Elahere to full approval for treating platinum-resistant ovarian cancer. A decision is due on Apr 5, 2024.
FDA Grants Priority Review of ImmunoGen's Supplemental Biologics License Application for ELAHERE® (mirvetuximab soravtansine-gynx) in Platinum-Resistant Ovarian Cancer
WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the US Food and Drug Administration (FDA) has filed the supplemental Biologics License Application (sBLA) supporting...
IMMUNOGEN INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of ImmunoGen, Inc. - IMGN
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of ImmunoGen, Inc. (NasdaqGS: IMGN) to AbbVie Inc. (NYSE: ABBV). Under the...
Are You Looking for a Top Momentum Pick? Why ImmunoGen (IMGN) is a Great Choice
Does ImmunoGen (IMGN) have what it takes to be a top stock pick for momentum investors? Let's find out.
AbbVie: 4 Hidden Keys Investors Must Know To Judge ImmunoGen Acquisition
AbbVie has agreed to acquire ImmunoGen for $10 billion, nearly double its previous trading price. The acquisition provides AbbVie with a commercial-stage company and a flagship drug that generated $105 million in sales in Q3. Let's look at this massive...
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen, Inc., (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the compensation committee of the Company's Board of Directors (the “Compensation Committee”) approved, effective as of...
ImmunoGen (IMGN) Just Flashed Golden Cross Signal: Do You Buy?
From a technical perspective, ImmunoGen (IMGN) is looking like an interesting pick, as it just reached a key level of support. IMGN recently overtook the 20-day moving average, and this suggests a short-term bullish trend.
AbbVie bolsters portfolio with $10.1 billion ImmunoGen buyout for cancer therapy
AbbVie has announced its acquisition of ImmunoGen for $10.1 billion in cash, marking a strategic move amidst rising competition for their leading treatment, Humira. ImmunoGen's Elahere, part of the innovative class of antibody-drug conjugates (ADC), specifically targets cancer cells, offering...
AbbVie (ABBV) to Acquire ImmunoGen (IMGN) for $10.1 Billion
AbbVie (ABBV) offers to buy ImmunoGen (IMGN) for approximately $10.1 billion, which will diversify its oncology pipeline across solid tumors and hematologic malignancies.
ImmunoGen stock nearly doubled on Thursday: what happened?
Shares of ImmunoGen Inc (NASDAQ: IMGN) close to doubled this morning after AbbVie Inc (NYSE: ABBV) said it will buy the cancer therapies company for $10.1 billion. ImmunoGen stock priced at a massive premium The all-cash transaction values each share...
Source: https://incomestatements.info
Category: Stock Reports